Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

2 terminated/withdrawn out of 10 trials

Success Rate

77.8%

-8.7% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

29%

2 of 7 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1

5(50.0%)

Phase 2

4(40.0%)

N/A

1(10.0%)

10Total

Phase 1(5)

Phase 2(4)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT02724917Phase 1Suspended

Safety, Tolerability, and Pharmacokinetics of APN1125 in Subjects With Schizophrenia

Role: lead

NCT02331433Phase 1Completed

Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects

Role: lead

NCT00414206Phase 2Terminated

Safety and Efficacy of ATG003 in Patients With Wet Age-Related Macular Degeneration (AMD)

Role: lead

NCT00783068Not ApplicableCompleted

Anti-inflammatory Effects of GTS-21 After LPS

Role: collaborator

NCT00607750Phase 2Completed

Safety and Efficacy of ATG003 in Patients With AMD Receiving Anti-VEGF

Role: lead

NCT00419445Phase 1Completed

Safety and Efficacy of GTS21 in Adults With Attention-deficit Hyperactivity Disorder

Role: lead

NCT00621010Phase 1Completed

Safety Study of CTS21166 to Treat Alzheimer Disease

Role: lead

NCT00536692Phase 2Completed

Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)

Role: lead

NCT00316537Phase 1Terminated

Safety and Preliminary Efficacy Study of Nicotine Gel to Treat Diabetic Foot Ulcers

Role: lead

NCT00414622Phase 2Completed

GTS21-201 for Alzheimer Disease:GTS-21 Administered Daily for 28 Days to Participants With Probable Alzheimer's Disease

Role: lead

All 10 trials loaded